Search

Ondansetron

A competitive serotonin type 3 receptor antagonist. … [L5221] The FDA withdrew its approval for the use of all intravenous drug products containing more than 16 mg of ondansetron hydrochloride in a single dose, due to a high risk of QT prolongation.

Betamethasone

Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties.

Nepidermin

Repaglinide

Repaglinide metabolites do not possess appreciable hypoglycemic activity. Approximately 90% of a single orally administered dose is eliminated in feces and 8% in urine. … Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight.

Fexofenadine

[A1452] Fexofenadine is the major active metabolite of [terfenadine][A1495] and is administered as a racemic mixture in which both enantiomers display approximately equivalent antihistamine activity.

Amlodipine

Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. … The option for single daily dosing of amlodipine is an attractive feature of this drug [FDA label].

Selenium Sulfide

Selenium Sulfide is the active ingredient often used in shampoos for the treatment of dandruff, seborrheic dermatitis and tinea capitis, a fungal infection that is primarily a disease of preadolescent … Selenium Sulfide is an antifungal agent as well as a cytostatic agent, slowing the growth of hyperproliferative cells in seborrhea.

Carbamide peroxide

As it is a source of hydrogen peroxide, it can be found in disinfecting and dental bleaching products. … Carbamide peroxide, also known as urea-hydrogen peroxide, is a water-soluble, white crystalline solid compound consisting of hydrogen peroxide and urea.

Cloxacillin

A semi-synthetic penicillin antibiotic which is a chlorinated derivative of [oxacillin].

Sunitinib

Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. … On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).